Get the Stockscreener App
2.77
8.58%
-0.26
Adc Therapeutics Sa stock is traded at $2.77, with a volume of 1.32M.
It is down -8.58% in the last 24 hours and up +28.84% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
See More
Previous Close:
$3.03
Open:
$3.07
24h Volume:
1.32M
Relative Volume:
2.43
Market Cap:
$364.17M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-0.939
EPS:
-2.95
Net Cash Flow:
$-121.90M
1W Performance:
-22.63%
1M Performance:
+28.84%
6M Performance:
+41.33%
1Y Performance:
+2.97%
1-Day Range:
$2.7325
$3.1403
1-Week Range:
$2.7325
$3.7543
52-Week Range:
$1.05
$4.13
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
2.77 | 364.17M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes - Quantisnow
Adc Therapeutics SA (NYSE: ADCT) Continues Its Downward Trend - Stocksregister
ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma - marketscreener.com
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial By Investing.com - Investing.com Nigeria
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial - Investing.com Australia
Breakthrough Lymphoma Treatment: ZYNLONTA Shows 85% Response Rate with 27-Month Durability in Latest Trial - Stock Titan
Switzerland: ADC Therapeutics raises US$100m from PIPE financing - Investors in Healthcare
ADC Therapeutics (NYSE:ADCT) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
Analysts Set Expectations for ADCT FY2026 Earnings - MarketBeat
Guggenheim Raises Price Target for ADC Therapeutics (ADCT) | ADCT Stock News - GuruFocus
ADC reports data from lymphoma trial, streamlines operations - MSN
ADC Therapeutics (ADCT) Price Target Raised Amid Strategic Moves - GuruFocus
ADC Therapeutics (ADCT) Secures $100M in PIPE Financing to Boost ZYNLONTA Development - GuruFocus
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $10.00 at Guggenheim - MarketBeat
ADC Therapeutics price target raised to $10 from $7 on positive trial data By Investing.com - Investing.com South Africa
ADC Therapeutics announces $100M private financing - MSN
ADC Therapeutics price target raised to $10 from $7 on positive trial data - Investing.com India
ADC Therapeutics (ADCT) Price Target Raised Amid Strategic Moves | ADCT Stock News - GuruFocus
ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress - The Malaysian Reserve
ADC Therapeutics raises $100 million in private placement By Investing.com - Investing.com South Africa
ZYNLONTA-glofitamab combo shows 93.3% response rate in lymphoma trial By Investing.com - Investing.com South Africa
ADC Therapeutics Tightens Belt And Targets New Frontiers - Finimize
Transcript : ADC Therapeutics SASpecial Call - MarketScreener
ADC Therapeutics Announces $100M Private Placement - TipRanks
ADC Therapeutics to Cut 30% of Workforce, Shutter UK Site - MarketScreener
ADC Therapeutics : Corporate and Clinical Update June 2025 - MarketScreener
ADC Therapeutics (ADCT) Secures $100 Million in Private Equity F - GuruFocus
Adc Therapeutics Announces Updated Data from Lotis-7 Clinical Trial Presented At the European Hematology Association 2025 Congress - MarketScreener
ADC Therapeutics (ADCT) Secures $100 Million in Private Equity Financing | ADCT Stock News - GuruFocus
ADC Therapeutics raises $100 million in private placement - Investing.com Australia
ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 - GuruFocus
Adc Therapeutics Announces $100 Mln Private Placement Extending Expected Cash Runway Into 2028 - marketscreener.com
ZYNLONTA-glofitamab combo shows 93.3% response rate in lymphoma trial - Investing.com
Wellington Management Group LLP Grows Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
Equities Analysts Issue Forecasts for ADCT FY2026 Earnings - Defense World
Millennium Management LLC Sells 301,277 Shares of ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
Two Sigma Investments LP Has $365,000 Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Two Sigma Advisers LP Grows Stake in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Wellington Management Group LLP Purchases 84,785 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
Squarepoint Ops LLC Increases Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Q1 2025 Earnings Call Transcript - MSN
Millennium Management LLC Decreases Stock Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Nuveen Asset Management LLC Purchases 22,989 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
ProShare Advisors LLC Increases Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Shares Sold by Bank of America Corp DE - MarketBeat
ADC Therapeutics (ADCT) Shares Decline Amid Market Movement | AD - GuruFocus
Adc Therapeutics SA (NYSE: ADCT) Jumps 2.28%, Turning Investors Away - Stocksregister
ADC Therapeutics SA (NYSE:ADCT) Stock Position Boosted by Deutsche Bank AG - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adc Therapeutics Sa Stock (ADCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 10% Owner |
Dec 11 '24 |
Buy |
3.04 |
100,000 |
304,500 |
13,145,712 |
| Redmile Group, LLC | 10% Owner |
Dec 04 '24 |
Sale |
2.07 |
25,352 |
52,479 |
15,566,731 |
| Redmile Group, LLC | 10% Owner |
Jul 01 '24 |
Buy |
2.81 |
400,000 |
1,124,000 |
15,669,217 |
| Redmile Group, LLC | 10% Owner |
Jul 01 '24 |
Buy |
2.81 |
400,000 |
1,124,000 |
12,995,040 |
1.86%
1.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):